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Abstract
This review is to know the magnitude of nonalcoholic fatty liver disease (NAFLD) among 
general population and risk group populations of the South Asian countries. A thorough 
search of evidence-based literature was conducted using the PubMed database with key 
words. Databases searched from inception to February 2017. Systematic search of the 
literature was conducted for studies pertaining. Prevalence of NAFLD in South Asia var-
ies from 13 to 34%. The Highest rate is in Bangladesh (34.34%) and lowest in Pakistan 
(13.5%). Prevalence of NAFLD is 15–80% among obese people, 25–60% with dyslipid-
emia and 33–55% in pre diabetics and diabetics. Nonalcoholic steatohepatitis (NASH) 
is present in about 50% of the NAFLD cases that can lead to fibrosis, cirrhosis or even 
hepatocellular carcinoma (HCC). NAFLD is not the disease for only obese people, but 
it is also common in nonobese in this region. About 11.11% hepatocellular carcinoma 
developed from NASH. Incidence rate of diabetes and coronary artery disease is high 
among NAFLD patients. NAFLD is becoming a future challenge for South Asia region. 
Prevalence and severity has been remarkably increasing for last few years. The health 
system should get ready to confront burden of NAFLD in future for South Asia.
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1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is a characterized by excessive accumulation of 
fat (defined as the presence of lipid in >5% of hepatocytes or a lipid content >5% of liver 
weight) [1] in the liver, who consume little (<20 g of alcohol/d) or no alcohol [1, 2]. It is the 
most common cause of chronic liver injury [3]. Worldwide millions of people are affected 
© 2018 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
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by the NAFLD and it is prophesied to be the following universal epidemic [4]. Universally 
its prevalence rate is 25.24 with highest in the Middle East and South America and lowest 
in Africa [5]. The NAFLD with necroinflammation, defined as nonalcoholic steatohepatitis 
(NASH) [2]. According to Younossi ZM, universally overall mortality for NAFLD is 1.05; and 
incidence of hepatocellular carcinoma (HCC) and liver-specific mortality among NAFLD is 
0.44 and 0.77 per 1000 person-years respectively. About 30% NAFLD progress to NASH, it 
can be lead to fibrosis, cirrhosis or even hepatocellular carcinoma [6]. HCC is one of the most 
common cancers worldwide and its burden is highest in the South-East Asia [7]. Countries 
with higher economic status tend to present a higher prevalence of NAFLD [8]. But it is not 
uncommon in low economic countries like countries of South Asia. The prevalence of NAFLD 
has increased remarkably over the years in South Asia and South-East Asia affecting 5–34% 
of general population [9, 10]. Metabolic syndrome common in people from South Asia is an 
important risk factor for NAFLD and Bangladeshi ethnicity is an important independent risk 
factor for NAFLD [3]. It is commonly described as hepatic manifestation of metabolic syn-
drome and insulin resistance. Though prevalence of NAFLD markedly increased in obese 
population, presence of NAFLD is further more challenging to diagnose and manage in lean 
population. In this study we aimed to know the prevalence NAFLD among general popula-
tion and risk group populations of the South Asian countries. We also explored the prevalence 
of NASH and its associated conditions.
2. Materials and methods
We performed a systematic PubMed/MEDLINE literature search with the following key 
words: “Non-alcoholic Fatty Liver Disease/epidemiology”[Mesh], “Non-alcoholic steatohepa-
titis” [Text word] AND “Liver Transplantation/etiology”[Mesh], “Obesity”[Mesh], “Diabetes 
Mellitus”[Mesh], “Global,” “Afghanistan,” “Pakistan,” “India,” “Sri Lanka,” “Maldives,” 
“Nepal,” “Bangladesh,” and “Bhutan.” Databases searched from inception to February 2017. 
Exclusions included data on alcohol consumption or other liver diseases. Relevant full article, 
abstract, review, mini review, editorial and conference proceeding are included in this review.
3. Global epidemiology
Nonalcoholic fatty liver disease (NAFLD) is the commonest liver disease with global prev-
alence of approximately 25.24% of the general population [5]. Nonalcoholic steatohepatitis 
(NASH) and NAFLD are not only a Western disease. NAFLD and NASH have increasingly 
been diagnosed in all regions of Asia [11]. A study using the National Health and Nutrition 
Examination Survey (NHANES) found a 30% prevalence of NAFLD in the United States 
between 2011 and 2012 [12]. NAFLD is the most common cause of chronic liver disease in 
Western countries. It affects about 1 billion individuals worldwide [13]. Increasing prevalence 
of NASH is closely associated with prevalence diabetes and obesity, which may defined as epi-
demic worldwide. At least 1.46 billion obese adult is persisting in the world. Approximately 
6 million individuals in the USA are in the risk of developing NASH and about 0.6 million 
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to develop NASH-related cirrhosis [14]. Table 1 shows estimated prevalence of NAFLD and 
NASH. Reports on the prevalence of NAFLD and NASH vary substantially due to varying 
definitions, differences in the populations studied, and the diagnostic methods used [14].
4. Delineation of South Asia and its population diversity
According to the United Nations geographic region ordering, South Asia comprised with 
Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka (Figure 1). 
Topographically, it is dominated by the Indian Plate; the terms “Indian subcontinent” and 
“South Asia” are sometimes used interchangeably [15]. South Asia is the most populated 
region in the world [16]. Socially it is very mixed, consisting of many language groups and 
religions, and social practices in one region that are vastly different from those in another [17].
Region Population studied Prevalence of NAFLD in these populations (%)
USA Pediatric population 13–14
General population 27–34
Europe Pediatric population 2.6–10
General population 20–30
Middle East General population 20–30
Far East General population 15
South Asia General population 5–30
Table 1. Estimated prevalence of NAFLD and NASH among different areas of the word.
Figure 1. Geographical position and area of South Asia [16].
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5. Prevalence of NAFLD among South Asian people
Recent socioeconomic changes have resulted in an emerging epidemic of non-communi-
cable diseases such as type 2 diabetes and nonalcoholic fatty liver disease. The prevalence 
of nonalcoholic fatty liver disease in Asian Pacific countries now approximates and even 
overrides levels encountered in Western countries in some studies [18]. NAFLD is the 
emerging challenge for public health issue in Asia [19]. This has a potential burden not 
only on liver disease but also on metabolic syndrome related morbidity: obesity, diabetes, 
and atherosclerotic cardiovascular disease [19]. Largest population of the world inhabiting 
in Asia are passing through an economic growth and shift of focus from a dominant physi-
cal activity to knowledge, capital and physical inactivity. An increasing GDP is paralleled 
by a rising body mass index (BMI) in an almost linear fashion [19]. Countries with higher 
economic status tend to present a higher prevalence of NAFLD [8]. It is believed to provide 
a distinctive epidemiologic perspective to global situation of NAFLD. Especially for South 
Asia, according to increasing with their economy the prevalence of NAFLD is increasing 
day by day.
Most of the available epidemiological studies in NAFLD from Asia are ultrasound based 
and hence detect prevalence of hepatic steatosis alone initially, correlating it with anthro-
pometric, biochemical, and demographic features of the population (Table 2). The com-
munity prevalence of NAFLD in South Asia and South-East Asia ranges from 5 to 30% [9, 
10]. Recently a hospital based study in Pakistan had shown a frequency of approximately 
14%. In India, it varies from 5 to 28% in general population, especially those who are 
undergoing health check-ups. Indians have increased propensity for visceral fat accumu-
lation which may present from birth [9]. Prevalence of NAFLD in general population of 
Bangladesh has been estimated to vary from 4 to 34.34% [20, 21], which exceeds previ-
ous reports and it jumps up to 49.8% in diabetic patients [22, 23]. And in Sri Lanka the 
prevalence rate was found 32.6 in an urban based study [24]. So it is seen that, among 
South Asian countries the highest magnitude of NAFLD is in Bangladesh and lowest is in 
Pakistan (Figure 2).
Country Population and place Sample size (n) Prevalence of NAFL
India Selected population Mumbai 1168 16.6%
General population West Bengal (rural) 1911 167 (8.7%)
General population Chennai (urban) 541 173 (32%)
Bangladesh General population Nation wide 2621 900 (34.34%)
Selected Population Camilla (rural) 665 219 (33%)
Sri Lanka General population (urban) 2985 974 (32.6%)
Pakistan Tertiary care hospital, Karachi 952 129 (13.5%)
Table 2. Prevalence of NAFLD among the Indian, Sri Lanka and Pakistani people.
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From the study of Alazawi et al. the prevalence of recorded NAFLD varied considerably by 
ethnic group. This study identified that Bangladeshi ethnicity as an independent risk factor for 
NAFLD. Diagnosed NAFLD was significantly more prevalent among people of Bangladesh 
ethnicity (1.8% of the adult population) than other ethnic group, including other South Asian 
groups. Among Bangladeshis, there are higher rates of type 2 diabetes and cardiovascular 
disease that may have a genetic basis. Transaminase were measured on 218,032 patients, of 
whom 31,627 had elevated serum transaminases. In a multivariate analysis, independent risk 
factors for NAFLD included Bangladeshi ethnicity, diabetes, raised BMI, hypertension, and 
hypercholesterolaemia. As expected, the prevalence of NAFLD was significantly lower in the 
African and Caribbean ethnic groups [19]. Female are predominant sufferers of NAFLD in 
Bangladesh [25]. So the prevalence of NAFLD in South Asia has been increased from previous 
reports and now it ranges from 14 to 34.34% in general population. In systematic searching 
in PubMed/MEDLINE database, we found research articles on epidemiology of NAFLD of 
India, Bangladesh, Sri Lanka and Pakistan. But we did not get any article relevant to the epi-
demiology of NAFLD of Afghanistan, Maldives, Nepal and Bhutan.
6. Prevalence of NASH and its progression
The active form of NAFLD is non-alcoholic steatohepatitis (NASH), which is characterized 
by hepatocyte injury with liver inflammation, and progression of fibrosis [26]. And it has 
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Figure 2. Prevalence of NAFLD in different countries of South Asia.
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emerged as one of the most important causes of liver failure and hepatocellular carcinoma. 
Up to 20% of cases NASH may progress to cirrhosis [27]. According to Alam et al. “Patients 
with NASH are at risk for progressive liver disease (which can progress to cirrhosis, hepato-
cellular carcinoma, and death from chronic liver disease), as well as cardiovascular mortality 
and type-2 diabetes” [25].
NASH is present in 42.4–53.1% cases of Bangladeshi NAFLD patients [25]. Diabetic is the prin-
ciple cause to develop NASH. A study in Indian Diabetic Mellitus (DM) patient; it reported that 
severe NASH is present among 9.35% Indian DM patients [28]. Ultrasound based Indian study 
showed the prevalence of NAFLD to be 16.6%, while a study based on liver biopsy showed 
the presence of NASH was 53% [29, 30]. And in Sri Lanka a liver biopsy based study were per-
formed on 296 patients and 100 (35.1%) were diagnosed as having NASH [31]. In another Asian 
study proven NASH at presentation was found in 32.6% patients of NAFLD [32].
Study from the West found that disease progression from NAFLD to NASH is 44% patients [33]. 
Multiple factors like obesity, insulin resistance, genetic factor, immune response and lipotoxic-
ity are involved in the progression of NAFLD to NASH [34]. In patients with cirrhotic NASH, 
HCC and liver failure are the main causes of morbidity and mortality. A prospective Japanese 
study elucidated the progression from NASH to HCC is 11.3% [35]. The prevalence of NASH 
(9.35–59%) among NAFLD patients is much higher in South Asian countries than that of Western 
countries. Severity of NAFLD in the form of NASH is also highest in Bangladesh among the 
South Asian countries as evidenced by recent studies from tertiary level hospitals of the country.
7. Depiction of the magnitude among different risk group
According to Alam, one fourth of the Bangladeshi NAFLD patients are nonobese; among 
them 53.1% cases present NASH. Male are largely dominating in nonobese group, where 
female are in obese group [36]. High BMI, central obesity, triglyceridemia and age are impor-
tant risk factors for Bangladeshi people, and risk factors contributed about 29% risk for the 
occurrence of NASH [37]. After adjusting the risk factors (BMI and TG) female gender is the 
independent risk for Bangladeshi [38]. Although insulin resistance (IR) is strongly associated 
with NAFLD, But IR is not the sole predictor in the pathogenesis of NAFLD [38–40].
In India the prevalence of NAFLD is 15–80% among obese people, 25–60% in patients with 
dyslipidemia and 33–55% in pre-diabetics and diabetics’ Indian people [41]. Most of the non-
diabetic NAFLD patients are overweight/obese with higher insulin resistance, dyslipidemia, 
and subclinical inflammation [42]. Among 65.7% Morbidly Obese South Indian Patients has 
NAFLD. Among them 33.6% were of NASH, 31.3% shows fibrosis and 14.1% shows advanced 
fibrosis [43]. The polymorphism T-455C in APOC3 gene and elevated serum triglycerides 
are associated with Indian NAFLD patients [44]. In another series, 56.5% T2DM patients 
have NAFLD, and the prevalence is higher in females (60%) than males T2DM patients [45]. 
NAFLD is the commonest liver disease in Indian psoriatic patients also [46]. Coronary artery 
disease (CAD) is more prevalent in the NAFLD compared to non-NAFLD; It is a surrogate 
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and fairly reliable marker of risk for CAD among type 2 diabetic patients [47]. According 
to Duseja NAFLD is the commonest cause of unexplained elevation of SGPT and crypto-
genic cirrhosis and hepatocellular carcinoma in Indian patients. Insulin resistance and full 
blown metabolic syndrome are highly prevalent in Indian patients with NAFLD [48]; 51.4% 
of patients of NAFLD have metabolic syndrome [49]. And it is really threatening news that 3% 
of 5–12 years Indian children have NAFLD [50].
In Sri Lanka Incidence rate of diabetes are 64.2 per 1000 person-years among NAFLD persons [51]. 
NAFLD is an independent predictor of developing diabetes mellitus [51]. Increased age and pres-
ence of NAFLD conferred a higher mortality risk from ACS as predicted by GRACE score [52].
As like developed countries obesity, insulin resistance, diabetes, dyslipidemia are the major 
risk factors for development of NAFLD. But the paradox is that it could develop in nonobese 
population also and one fourth of NAFLD of South Asia is from nonobese people.
8. Global and South Asian publication trend on NAFLD
According to Zhang et al. study, with the globally increasing prevalence, nonalcoholic fatty 
liver disease (NAFLD) becomes the predominant cause of chronic liver disease. The global 
scientific research articles relevant to NAFLD revealed 6356 articles were published in 994 
different journals during 1986–2013. Starting from the late 1980s, the publication on NAFLD 
grew slowly and entered into a highly developing period in the 21st century, especially in 
the last decade (Figure 3). Bibliometric results suggest that the obviously rapid growth of the 
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Figure 3. Trend of number of publication on NAFLD of South Asia (published in PubMed).
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articles in recent years appears to be associated with the accelerating incidence of NAFLD 
and its cofactors such as metabolic syndrome. In this study we found that, from inception 
to 2012 only 16 Indian research articles have been published in PubMed. Where from 2013 
to 2016 total 85 research articles of India, Bangladesh, Sri Lanka and Pakistan has been pub-
lished in PubMed (Figure 4). This phenomenon indicate that, how NAFLD is growing in 
South Asia.
9. Conclusion
The increase in NAFLD will continue to burden the health care system, especially because of 
its association with obesity, IR and metabolic syndrome. Along with globalization the prev-
alence of NAFLD is increasing alarmingly. The prevalence of NAFLD has been increasing 
remarkably for the last 12 years. Currently it is not only a disease of the Western countries 
but also becoming a major challenge for South Asia region. NAFLD is not the disease for only 
obese people, but it is also common in nonobese. And if the condition remains untreated it 
can turn into cirrhosis and hepatocellular carcinoma. It is really a great threat for us that, 
NAFLD is being seeing among our subcontinent’s children also. The burden of NAFLD and 
its severity projects that obviously it will be the biggest frontier of Hepatology in South Asia 
in near future.
Figure 4. Article on NAFLD publication in South Asia Trend in PubMed from inception-2016.
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